GlassScriptPhysician profile
Marie Minani
NPI 1710744412
$4,277.07
in general payments reported to CMS, 2019-2025
24 companies · $2,954 in 2025
The $2,954 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,323 · 2025: $2,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,265 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,264.92 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $587.06 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $538.57 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $506.24 | 2024-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $388.47 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $354.03 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $328.25 | 2024-2025 | Auvelity |
| Alkermes, INC. | $295.85 | 2024-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $253.00 | 2024-2025 | Ingrezza |
| Bausch Health US, LLC | $221.18 | 2025 | Wellbutrin, Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $162.10 | 2025 | Cobenfy |
| Lundbeck LLC | $133.49 | 2024-2025 | Rexulti |
| Noven Therapeutics, LLC | $75.70 | 2025 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $67.62 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Almatica Pharma LLC | $63.83 | 2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $53.81 | 2024-2025 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $50.56 | 2025 | Jornay Pm |
| Corium, LLC | $33.85 | 2025 | Azstarys |
| Neos Therapeutics, LP | $31.02 | 2024-2025 | Adzenys Xr-Odt |
| Biogen, INC. | $29.66 | 2025 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $26.90 | 2024 | |
| Livanova USA, INC. | $22.84 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Braeburn INC. | $20.39 | 2025 | Brixadi |
| Idorsia Pharmaceuticals US INC | $18.92 | 2024 | Quviviq |
| Tris Pharma INC | $13.73 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Minani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.